Which molecular features define CJC-1295 before a mass spectrum is acquired?
Identity assessment begins with a complete structure declaration. The modified GRF(1-29) core contains D-alanine at position 2, glutamine at position 8, alanine at position 15 and leucine at position 27 relative to native human GRF(1-29). For the commonly described CJC-1295 DAC construct, the structural declaration must also account for an added C-terminal lysine residue bearing a maleimidopropionyl group on its side-chain amino group, together with the terminal amidation state. Describing this only as an optional linker on an otherwise unchanged 29-residue peptide is inadequate for mass calculation. Published work on the albumin-binding construct provides structural context (PMID:15817669).
Material marketed as non-DAC CJC-1295 is commonly modified GRF(1-29) amide and should be documented by its actual sequence rather than inferred from that catalogue name. Calculate the theoretical mass from the complete structure, including any added residue, linker, attachment site and terminal modification. Conversion of a terminal free acid to an amide lowers neutral monoisotopic mass by approximately 0.9840 Da. D- and L-alanine have identical masses, so including a D-residue in the declared sequence does not make its stereochemistry verifiable by routine intact MS.
Replacing methionine with leucine removes that methionine oxidation site, but does not exclude oxidation elsewhere. Maleimide ring hydrolysis adds approximately 18.0106 Da; thiol adducts and incomplete coupling can produce other distinct species. Counter-ions and residual water affect material composition and gravimetric peptide content, not the theoretical neutral mass of the specified peptide. Associated adducts can nevertheless appear in experimental spectra.
How is CJC-1295 peptide mass spectrometry identity assessed from intact-mass data?
Positive-mode electrospray commonly produces several multiply charged ions for these peptides. The observed charge envelope depends on structure, solvent and source conditions; a particular charge-state range is not an identity requirement. Deconvolution should compare like with like: neutral monoisotopic mass with theoretical monoisotopic mass, or average mass with the corresponding theoretical average mass. A protonated-ion mass must not be compared directly with a neutral-mass calculation.
High-resolution results should include mass error, usually in parts per million, alongside the acquisition and processing method. A 5-10 ppm window can be an illustrative criterion for a suitably calibrated method with reliable isotope assignment, but it is not a universal acceptance limit. Laboratories should establish criteria through method qualification or validation, considering signal quality, resolving power, isotope selection and reference performance. Printing additional decimal places does not demonstrate accuracy.
Low-resolution measurements generally provide nominal-mass consistency rather than confident discrimination of closely related species. For multiply charged ions, a neutral-mass difference is divided by charge in the observed m/z separation. Deamidation therefore cannot be assumed distinguishable simply because a deconvoluted result is reported to a fraction of a dalton.
Sodium or potassium adducts, solvent or counter-ion associations and overlapping species require explicit interpretation. A hydrolysed DAC species should be distinguished from the parent, not incorporated into an averaged identity result. Identification of CJC-1295 in an unknown preparation illustrates the role of mass-spectrometric characterisation (PMID:21204297). For a research lot, archive the raw spectrum, processing parameters, calibration or system-suitability evidence and sample-to-lot mapping.
Which LC-MS/MS fragment ions distinguish CJC-1295 from related GHRH analogues?
Intact mass alone does not uniquely establish sequence. Isomeric residues, stereoisomers and compensating structural changes can remain indistinguishable. Tandem MS adds evidence by comparing assigned product ions with predictions for the declared structure. Collision-based fragmentation commonly yields b- and y-type ions, although the usable fragment series and sequence coverage depend on precursor charge, fragmentation conditions and modifications.
For otherwise equivalent singly charged fragments, replacing methionine with leucine decreases monoisotopic mass by approximately 17.9564 Da; the m/z difference is divided by charge for multiply charged fragments. Attribution requires fragments that localise the relevant residue, not merely a peak somewhere near that offset. Routine mass measurements do not distinguish leucine from isoleucine or D-alanine from L-alanine. Stereochemical claims need suitable orthogonal evidence where they are material to the specification.
Fragments retaining the modified C-terminal region can support assignment of the DAC construct, provided the additional residue and linker attachment are included in the theoretical fragment calculation. Tesamorelin has a different declared structure, including an N-terminal hexenoyl group and a longer GHRH sequence; discrimination should use the full precursor and fragment pattern rather than the absence of one increment alone.
Published equine-plasma confirmation methods and detection reviews illustrate targeted analytical approaches (PMID:30938069; PMID:34665524). Immunoaffinity enrichment can assist analysis of peptide hormones in complex matrices, but is not automatically necessary for a neat synthetic lot (PMID:21871962). Immuno-PCR provides a different type of evidence and does not establish exact mass or sequence (PMID:30489688). A tandem-MS report should state precursor m/z and charge, fragmentation conditions, assigned ions, mass errors and coverage limitations. Targeted transitions support identification only within a demonstrated selective method; full-scan product-ion data do not automatically establish complete sequence or impurity identity.
What certificate-of-analysis fields should document mass-spectrometric identity?
The CoA, or an explicitly linked analytical report, should separate identity, chromatographic related substances and peptide content. Useful identity fields include the declared sequence and modifications; DAC status and attachment details; theoretical and observed mass; monoisotopic or average-mass convention; mass error with units; ionisation mode; instrument and method identifiers; analysis date; and a traceable sample-to-lot identifier. Raw analytical filenames need not literally equal the lot number, but their mapping must be documented.
If tandem MS was performed, report or link to precursor details, assigned product ions and the extent of sequence support. If only intact mass was measured, say so and avoid implying complete sequence or stereochemical confirmation. Retention-time agreement against an appropriate reference is complementary evidence, not a substitute for structural characterisation.
A one-line conforms result can be an acceptable summary only when the specification, method and supporting data are traceable; on its own it provides little basis for independent assessment. A high HPLC area percentage cannot establish that the main peak is the correctly labelled analogue. The unknown-preparation identification study illustrates why analytical evidence matters beyond a printed name (PMID:21204297).
Peptide content may be assessed by a suitably validated quantitative method, such as amino-acid analysis or another justified assay. Nitrogen determination alone requires assumptions about counter-ions and other nitrogen-containing components. Water and counter-ion results should be reported where relevant to the content calculation, without double correction. Impurity assignments should distinguish confirmed structures from tentative mass-based proposals; an oxidation-sized offset alone does not localise oxidation.
How do sample preparation and complementary HPLC support an MS identity assessment?
Sample preparation can change the species observed, so the diluent, concentration, preparation time, storage conditions and analysis interval should be controlled. An MS-compatible volatile mobile phase, often using formic acid, can reduce the ion-suppression problems associated with TFA. Any change from the chromatographic method should be evaluated for solubility, recovery, stability and separation rather than assumed equivalent.
Adsorption to containers and preparation-related degradation can bias the observed composition. Suitable low-binding materials, stability checks and controlled contact times help assess those risks. DAC material warrants attention to maleimide hydrolysis and unintended reactions with thiol-containing sample components.
Reversed-phase HPLC with UV detection offers complementary chromatographic information. Area normalisation, including detection around 214 nm, describes the detected peak areas under the stated conditions; it is not automatically mass-fraction purity or net peptide content. Co-elution, differing response factors and undetected components limit interpretation. An LC-MS experiment or analysis of a collected fraction can associate a chromatographic peak with a mass, but a collected peak can still contain more than one species. The degree of analytical orthogonality depends on the separation and detection methods used.
Document the column, gradient, detector settings, integration rules and relevant system-suitability criteria. Complex-matrix enrichment and confirmation workflows provide useful methodological context, not a universal requirement for synthetic-lot analysis (PMID:21871962; PMID:30938069). Immuno-PCR screening likewise does not replace structural evidence (PMID:30489688). Unexpected mass offsets should prompt investigation of preparation artefacts, degradation, synthesis-related species and labelling errors rather than an automatic assignment to any one cause.
How should Australian research laboratories reconcile lot labels with MS reports?
Research-lot assessment should reconcile the declared structure, lot label, CoA and analytical sample records. Laboratories should obtain documentation applicable to the received lot, rather than treating an example certificate as evidence for every shipment. Where several lots are supplied, each needs appropriate lot-specific evidence or a documented sampling and release rationale. Testing one vial does not independently demonstrate the identity or homogeneity of every vial carrying the same lot number.
An unexplained identifier mismatch is a traceability nonconformance, not proof of a chemical identity failure. Hold the affected material from laboratory use while the discrepancy is investigated. A mass result outside the applicable criterion similarly requires investigation before acceptance or any change to the identity claim.
Australian stock location and tracked dispatch do not establish chemical identity, shorten chain of custody by themselves or demonstrate regulatory status. Relevant records instead include the documented supply chain, receipt condition, lot mapping and analytical evidence. Retain spectra, chromatograms and method references where available, with raw data access or archival arrangements appropriate to the laboratory's quality system.
Research-use-only wording does not itself establish that importation, supply or a particular use is lawful, nor does a CoA establish TGA approval. Applicable Australian requirements should be assessed separately. The analytical record should contain no human-use instructions. Reviews of GHRH-analogue detection provide context for the need to distinguish related structures carefully (PMID:34665524).
Order Cjc 1295 with documentation
If this guide helped you evaluate Cjc 1295 for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Cjc 1295 card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Does an HPLC purity percentage confirm CJC-1295 identity?
No. HPLC area percentage describes detected chromatographic peak areas under a specified method. It does not establish sequence, stereochemistry or mass-fraction purity. Identity assessment needs evidence matched to the declared structure, with intact mass, informative fragments and other methods used according to the specificity required.
What mass-error window should be used for intact-mass identity?
Use a predefined, method-supported acceptance criterion. A 5-10 ppm window is an illustrative high-resolution criterion, not a universal specification. Calibration, isotope assignment, charge, signal quality and the mass convention all matter. Low-resolution data should not be assumed capable of resolving deamidation or other near-isobaric differences.
How do DAC and non-DAC CJC-1295 differ on a mass spectrum?
The commonly described DAC construct includes an added C-terminal lysine bearing a maleimidopropionyl group, so its theoretical mass must include more than a linker alone. Material commonly marketed as non-DAC CJC-1295 is modified GRF(1-29) amide. Calculate both from fully specified structures. Maleimide hydrolysis adds approximately 18.0106 Da to the DAC parent, but that offset alone is not complete structural proof.
Which CoA fields should an Australian research laboratory check?
Check the declared sequence and modifications, theoretical and observed masses, mass convention, error units, analytical method, lot mapping and any linked supporting data. Keep chromatographic area percentages separate from peptide content. Local dispatch and a research-use-only label do not establish identity or regulatory approval.
Is tandem MS required for every research lot?
There is no universal rule. A qualified release strategy may use intact mass alongside other established controls, but intact mass alone does not prove sequence or stereochemistry. Tandem MS is useful when localisation of residues or modifications is needed; even then, coverage and isomeric limitations must be stated.
Can an immunoassay replace mass spectrometry for CJC-1295 identity?
An immunoassay measures recognition by a binding reagent, not exact molecular mass or sequence. Published immuno-PCR work concerns screening in equine plasma (PMID:30489688). Such evidence is not interchangeable with mass-spectrometric characterisation of a research lot.
References
- PMID:15817669 — Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog — Endocrinology — 2005
- PMID:21204297 — Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation — Drug Test Anal — 2010
- PMID:21871962 — Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls — Methods — 2012
- PMID:30489688 — An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma — Drug Test Anal — 2019
- PMID:30938069 — A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS — Drug Test Anal — 2019
- PMID:34665524 — Advances in the detection of growth hormone releasing hormone synthetic analogs — Drug Test Anal — 2021
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
